Persantin Preceding Elective PCI (P3)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
In this study the investigators will investigate whether a short pretreatment (3-7 days) with dipyridamole 200mg twice daily will protect patients against myocardial injury sustained during an elective dotter operation of the coronary arteries (PCI).
The investigators hypothesize that dipyridamole can reduce myocardial injury sustained during elective PCI.
| Condition | Intervention | Phase |
|---|---|---|
|
Coronary Heart Disease Percutaneous Transluminal Coronary Angioplasty Atherosclerosis |
Drug: dipyridamole Drug: placebo |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Prevention |
| Official Title: | Does Pretreatment With Persantin Reduce Periprocedural Troponin-I Release in Patients Undergoing Elective Single Vessel PCI |
- Cardiac troponin-I [ Time Frame: before and 8 hours after PCI ] [ Designated as safety issue: No ]
- Effect of pretreatment with dipyridamole 2x200mg on biomarkers reflecting vascular inflammation (hs-CRP, PLA2, PTX3, IL-6, adiponectin, MCP-1, MMP-9) [ Time Frame: 3 days treatment minimal ] [ Designated as safety issue: No ]
- Effect of PCI on biomarkers reflecting vascular inflammation (hs-CRP, PLA2, PTX3, IL-6, adiponectin, MCP-1, MMP-9) [ Time Frame: before and 8 hours after PCI ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 200 |
| Study Start Date: | October 2008 |
| Estimated Primary Completion Date: | May 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: 1
dipyridamole
|
Drug: dipyridamole
dipyridamole slow release 200mg twice daily, minimal 3 days pretreatment
Other Name: persantin
|
|
Placebo Comparator: 2
placebo
|
Drug: placebo
placebo twice daily, minimal three days pretreatment
|
Detailed Description:
Rationale:
In elective PCI (percutaneous coronary intervention) up to 40% of the patients show an asymptomatic rise in myonecrosis marker troponin-I. This release of troponin-I has been found to represent irreversible myocardial injury and has been related to an increased risk of restenosis and even long-term mortality. Dipyridamole has been proven to induce protection against ischemia reperfusion injury and to reduce risk of cardiovascular death or event in secondary prevention after TIA or CVA.
Objective:
To test the hypothesis that dipyridamole improves tolerance to ischemia reperfusion injury in patients undergoing elective PCI.
Study design:
Double-blind placebo controlled intervention study
Study population:
Patients undergoing elective PCI
Intervention:
pretreatment with dipyridamole (Persantin Retard) 2dd 200mg or placebo.
Main study parameters:
Periprocedural troponin-I release measured 8 hours after PCI.
Bioequivalence study:
before the start of th clinical trial we will perform a bioequivalent study to test whether our study medication (blinded by recapsuling) equals original dipyridamole capsules. 6 Healthy volunteers in a cross-over randomised design will take original dipyridamole 200 mg SR and recapsuled dipyridamole 200mg SR (prepared by the department of pharmacy of the RUNMC). Plasma dipyridamole concentration will be measured frequently and at baseline and 1 and 3 hours after administration of dipyridamole nucleoside transport inhibitions of erythrocytes will be measured, to assess drug activity.
The clinical trial will only be initialized after conformation of bioequivalence of the study medication to the original dipyridamole.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients accepted for elective single, native vessel (left anterior descending, right coronary artery or ramus circumflexus (LAD, RCA or RCX)) PCI in the RUNMC
- Troponin-I < 0,20 mmol/L at screening
- Signed Informed consent
Exclusion Criteria:
- unstable angina
- recent myocardial infarction (STEMI or non-STEMI), during two weeks prior to inclusion
- 3-Vessel disease as seen on coronary angiogram
- Stenotic lesion in main stem as seen on coronary angiogram
- CABG in medical history
- asthma (recurrent episodes of dyspnoea and wheezing, or usage of prescribed inhalation medication: i.e. corticosteroids or B2-agonists)
- Treatment with insulin
- Use of prescribed oral anticoagulants (coumarin derivates)
- Use of oral corticosteroids
- Use of sulfonylurea derivates (glibenclamide, tolbutamide, gliclazide, glimepiride)
- Use of heparin or low molecular weight heparin
- Use of metformin
- Use of dipyridamole
- Chronic use of Non Steroid Anti-Inflammatory Drugs (NSAID's)
Contacts and Locations| Netherlands | |
| RUNMC | |
| Nijmegen, Netherlands, 6500HB | |
| Canisius Wilhelmina Hospital | |
| Nijmegen, Netherlands, 6532SZ | |
| Principal Investigator: | Gerard Rongen, MD PhD | RUNMC |
More Information
Publications:
| Responsible Party: | G. Rongen MD PhD, RUNMC |
| ClinicalTrials.gov Identifier: | NCT00767663 History of Changes |
| Other Study ID Numbers: | P3 |
| Study First Received: | October 6, 2008 |
| Last Updated: | August 10, 2011 |
| Health Authority: | Netherlands: Medical Ethics Review Committee (METC) Netherlands: Medicines Evaluation Board (MEB) |
Additional relevant MeSH terms:
|
Atherosclerosis Coronary Artery Disease Myocardial Ischemia Coronary Disease Heart Diseases Arteriosclerosis Arterial Occlusive Diseases Vascular Diseases Cardiovascular Diseases Dipyridamole |
Phosphodiesterase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Platelet Aggregation Inhibitors Hematologic Agents Therapeutic Uses Vasodilator Agents Cardiovascular Agents |
ClinicalTrials.gov processed this record on May 16, 2013